Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma

European Urology

Volumn 55, Issue 6, 2009, Pages 1490-1491

  Gattenlohner S ^a   Etschmann, B ^a   Riedmiller, H ^a   Muller Hermelink H K ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PANITUMUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; DNA SEQUENCE; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LETTER; METASTASIS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 65249129254     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.02.024     Document Type: Letter

References (5)

1. Langner C., Ratschek M., Rehak P., Schips L., and Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?. J Clin Pathol 57 (2004) 773-775
2. Rowinsky E.K., Schwartz G.H., Gollob J.A., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22 (2004) 3003-3015
3. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008) 1757-1765
4. Gattenlohner S., Germer C., and Muller-Hermelink H.K. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360 (2009) 835
5. Lee S.J., Lattouf J.-B., Xanthopoulos J., Linehan W.M., Bottaro D.P., and Vasselli J.R. Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur Urol 54 (2008) 845-854